SCHEMBL7133202

SCHEMBL7133202

COc1c(C(=O)OCc2ccccc2)ccc2c1C(Sc1ccccc1)CS2(O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
TDP1 Q9NUW8 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.37
TSHR P16473 2/20 0.37
CYP3A4 P08684 1/20 0.37
MAPK1 P28482 1/20 0.37
RAB9A P51151 2/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37
PKM P14618 1/20 0.37
POLB P06746 2/20 0.37
KMT2A Q03164 2/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A3 Q01959 1/20 0.36
MEN1 O00255 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
ELANE P08246 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7133208 0.90 ALDH1A1 (0.39) ALDH1A1TDP1L3MBTL1TSHRCYP3A4
SCHEMBL7129935 0.83 ELANE (0.33) ELANE
SCHEMBL7135145 0.81 PLK1 (0.37) ALDH1A1L3MBTL1RAB9APOLBKMT2A
SCHEMBL7131227 0.80 ALDH1A1 (0.38) ALDH1A1TDP1L3MBTL1TSHRCYP3A4
SCHEMBL7128962 0.77 CYP1A2 (0.47) ALDH1A1TDP1L3MBTL1TSHRCYP3A4
SCHEMBL7131230 0.72 ALDH1A1 (0.38) ALDH1A1TDP1L3MBTL1TSHRCYP3A4
SCHEMBL7128212 0.71 ALDH1A1 (0.46) ALDH1A1TDP1L3MBTL1TSHRCYP3A4
SCHEMBL27869087 0.70 ALDH1A1 (0.45) ALDH1A1TDP1L3MBTL1TSHRCYP3A4
SCHEMBL7128215 0.70 ALDH1A1 (0.45) ALDH1A1TDP1L3MBTL1TSHRCYP3A4
SCHEMBL7135148 0.70 PLK1 (0.37) ALDH1A1L3MBTL1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO ALDH1A1 3159/4885TDP1 2238/4885L3MBTL1 2967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.